Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Kim ES, et al. Among authors: kies ms. Cancer. 2005 Aug 1;104(3):561-9. doi: 10.1002/cncr.21188. Cancer. 2005. PMID: 16028213 Free article. Clinical Trial.
Novel therapeutics for head and neck cancer.
Kim ES, Kies M, Herbst RS. Kim ES, et al. Curr Opin Oncol. 2002 May;14(3):334-42. doi: 10.1097/00001622-200205000-00014. Curr Opin Oncol. 2002. PMID: 11981281 Review.
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E Jr, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Shin DM, et al. Among authors: kies ms. Cancer. 2002 Jul 15;95(2):322-30. doi: 10.1002/cncr.10661. Cancer. 2002. PMID: 12124833 Free article. Clinical Trial.
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. Herbst RS, et al. Among authors: kies ms. Cancer. 2002 Jul 15;95(2):340-53. doi: 10.1002/cncr.10629. Cancer. 2002. PMID: 12124835 Free article. Clinical Trial.
ZD1839 (Iressa) in non-small cell lung cancer.
Herbst RS, Kies MS. Herbst RS, et al. Among authors: kies ms. Oncologist. 2002;7 Suppl 4:9-15. doi: 10.1634/theoncologist.7-suppl_4-9. Oncologist. 2002. PMID: 12202783 Free article. Review.
230 results